` ANVS (Annovis Bio Inc) vs S&P 500 Comparison - Alpha Spread

ANVS
vs
S&P 500

Over the past 12 months, ANVS has underperformed S&P 500, delivering a return of -18% compared to the S&P 500's +14% growth.

Stocks Performance
ANVS vs S&P 500

Loading
ANVS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ANVS vs S&P 500

Loading
ANVS
S&P 500
Difference
www.alphaspread.com

Performance By Year
ANVS vs S&P 500

Loading
ANVS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Annovis Bio Inc vs Peers

S&P 500
ANVS
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Annovis Bio Inc
Glance View

Market Cap
96.7m USD
Industry
Biotechnology

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2020-01-29. The firm is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The firm's lead compound, ANVS401, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The firm's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as ANVS401, but it is given intravenously in cases of acute head and brain trauma. The firm is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.

ANVS Intrinsic Value
Not Available
Back to Top